Citigroup Maintains Buy on Abbott Laboratories, Lowers Price Target to $122
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice TargetHot
Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $125 to $122.
Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $125 to $122.